Everything below concerns actin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Based on crystallography data of homologous NADP-dependent malic enzymes of mammalian origin, a 3D model for C4 pathway NADP-ME in plants has been developed, identifying the key residues involved in substrate-binding or catalysis. Dinucleotide binding involves two glycine-rich GXGXXG motifs, a hydrophobic groove involving at least six amino acid residues, and a negatively charged residue at the end of the βB-strand. The primary sequence of the first motif, 240GLGDLG245, is a consensus marker for phosphate binding, evidencing involvement with NADP binding, while the other glycine rich motif adopts a classical Rossmann fold—also a typical marker for NADP cofactor binding. Mutagenesis experiments in maize NADP-ME have supported the current model. Valine substitution for glycine in either motif region rendered the enzyme completely inactive while spectral analysis indicated no major changes from wild-type form. The data is suggestive of direct impairment at a key residue involved in binding or catalysis rather than an inter-domain residue influencing conformational stability. Additionally, a key arginine residue at site 237 has been shown to interact both with malate and NADP+ substrates, forming key favorable electrostatic interactions to the negatively charged carboxylic-acid and phosphate group respectively. Elucidation of whether the residue plays a role in substrate binding or substrate positioning for catalysis has yet to be determined.
== Personal life == Kearon is married to Jennifer Carole Hulme. They met while Hulme was a student at Brigham Young University spending a semester studying abroad in London, and they were married in the Oakland California Temple in 1991. They have four children, the oldest of whom died from a heart condition at three weeks old.
Rhodiola rosea (commonly golden root, rose root, roseroot, Aaron's rod, Arctic root, king's crown, lignum rhodium, orpin rose) is a perennial flowering plant in the family Crassulaceae. It grows naturally in wild Arctic regions of Europe (including Britain), Asia, and North America (New Brunswick, Newfoundland and Labrador, Nova Scotia, Quebec; Alaska, Maine, New York, North Carolina, Pennsylvania, Vermont), and can be propagated as a groundcover. Although Rhodiola rosea has been used in traditional medicine, there is no high-quality clinical evidence of its effectiveness to treat any disease. The United States Food and Drug Administration has issued several warnings to manufacturers of R. rosea based dietary supplements for making false health claims about safety and efficacy. The plant is threatened in many countries due to rapidly growing demand. R. rosea has been identified by various farmers and researchers as a potential cash crop naturally suited for cultivation in Arctic climates. Supply comes mostly from wild harvesting on an industrial scale, and a combination of growing scarcity and a lack of regulation has led to environmental degradation, substitution or adulteration in the market, and illegal harvesting in protected areas.
Sources: en.wikipedia.org
The brown bear has a hump between its shoulders, a distinction from other bear species. This hump is formed by large muscles, allowing for a wide range of motion, which the bear mainly uses to put pressure on the soil as it digs for food. The bison also has a hump between its shoulders, made almost entirely of muscle and supported by long skeletal spines. The bison hump's purpose is to hold up the animal's large head, and also enables the animal to use its head as a snow shovel in the winter, swinging it side to side with its hump muscles. Such foraging behavior sets the bison apart from other ungulates, which typically use their feet to scrape away snow. Moose, similarly, have a shoulder hump of muscle that is necessary to hold up their large head and, in males, antlers.
=== Preregistration submission withdrawal === Frovatriptan (Allegro; Auradol; EN-3266; Frova; Isimig; Migard; Pitunal; Rilamig; SB-209509; SB-209509AX; VML-251) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – menstrual migraine [38]
Carboxylation of the 2,3-enediolate results in the intermediate 3-keto-2-carboxyarabinitol-1,5-bisphosphate and Lys334 is positioned to facilitate the addition of the CO2 substrate as it replaces the third Mg2+-coordinated water molecule and add directly to the enediol. No Michaelis complex is formed in this process. Hydration of this ketone results in an additional hydroxy group on C3, forming a gem-diol intermediate. Carboxylation and hydration have been proposed as either a single concerted step or as two sequential steps. Concerted mechanism is supported by the proximity of the water molecule to C3 of RuBP in multiple crystal structures. Within the spinach structure, other residues are well placed to aid in the hydration step as they are within hydrogen bonding distance of the water molecule.
=== 2 February === According to a South Korean news report, North Korea was planning to send up to 500 military and police personnel to Russian-occupied Donbass after pulling back on a previous plan to send workers. Police stated that a Russian missile destroyed an apartment building in Kramatorsk, killing at least three people and injuring 20 others. EU officials visited Kyiv.
Sources: en.wikipedia.org
The violence flared up again at a performance at the Electric Ballroom in Camden Town in September, with bottles thrown at the band while they played, and a section of the audience smashing up the amplification equipment and smashing the lights afterwards, with several people injured by flying glass. A major factor in the audience reaction was the length of the band's sets at the time, which lasted less than twenty-five minutes, Jim explaining this with "there's never been a group good enough to play any longer". Lack of songs was also a factor, according to Jim: "We've only got enough songs to play for that long". After the success of the album in the UK, the band embarked on a tour of the United States in late 1985 and 1986, followed by a tour of Japan. On returning to the UK they toured the UK, this time without the trouble that had marred earlier performances. The band revived their acoustic intentions with a stripped-down session for John Peel in November 1985, which included "Psychocandy", the original album title track that was omitted from the release, and "Some Candy Talking", a song which they had been performing for over a year, but had been left off the album. A second version of "Some Candy Talking" was issued on a free EP issued with the NME in January 1986, and the song was released as the band's next single in July.
== Provisions and effects == The executive order explicitly rescinded 68 executive orders and 11 presidential memoranda from the Biden Administration. It also ordered heads of federal agencies to "take immediate steps to end Federal implementation of unlawful and radical DEI ideology". Additionally the order ordered, the Director of the Domestic Policy Council (DPC) and the Director of the National Economic Council (NEC) should review all Federal Government actions taken in accordance to the rescinded orders and take necessary steps to rescind, replace, or amend such actions when appropriate. It also ordered that within 45 days (before March 6), the DPC and NEC Directors should give the President further orders, issued by the prior administration that should be rescinded, as well as a list of "replacement orders, memoranda, or proclamations, to increase American prosperity". Lastly, it ordered the National Security Advisor (NSA) to review all Biden era National Security Memoranda for "harm to national security, domestic resilience, and American values" and within 45 days recommend a list for rescindment. The rescission of Biden's Executive Order 14074 deactivated the National Law Enforcement Accountability Database which tracked federal police misconduct.
This transformation of obsidian is accelerated by the presence of water. Although newly formed obsidian has a low water content, typically less than 1% water by weight, it becomes progressively hydrated when exposed to groundwater, forming perlite.
(+)-Menthofuran synthase (EC 1.14.14.143, menthofuran synthase, (+)-pulegone 9-hydroxylase, (+)-MFS, cytochrome P450 menthofuran synthase) is an enzyme with systematic name (+)-pulegone,NADPH:oxygen oxidoreductase (9-hydroxylating). This enzyme catalyses the following chemical reaction
TNFR provides specificity for the drug target and the antibody Fc segment is believed to add stability and deliverability of the drug. Additional chimeric proteins used for therapeutic applications include:
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.